What are the latest funding news in the neurotechnology market? (October 2026)
Every funding round, every investor, and who is really ahead in neurotech, in one document. Have a look ↓
Neurotechnology funding remained active through October 2026, with recent deals concentrated around brain-computer interfaces, neuromodulation, neural decoding and EEG monitoring.
The 12 most recent qualifying deals range from a $0.92M pre-seed round to a $250M Series D, showing a market that now spans early research translation through commercial growth.
China accounts for most of the recent deal flow, while the largest individual financing came from the United States.
And if you want to better understand this new industry, you can get our report on neurotech funding, valuations and who's ahead.
Insights
- China represents 8 of the 12 latest neurotechnology funding deals, or about 67%, with particularly strong activity across invasive BCI, focused-ultrasound neuromodulation and closed-loop neural systems.
- Precision Neuroscience's $250M Series D is more than five times Active Technology's roughly $46M angel round, showing how dramatically funding levels vary between mature clinical BCI companies and emerging platforms.
- At least five companies in this list explicitly combine neural sensing with stimulation, suggesting that closed-loop neurotechnology is becoming a central product architecture rather than a niche research direction.
- BCI is the dominant theme in this funding window: nine of the 12 companies either position brain-computer interfaces as a core product or build technology directly integrated into BCI systems.
- Active Technology's roughly $46M angel financing is larger than Epitel's $26M Series B, highlighting how capital-intensive invasive neural-interface development can become even before commercial scale.
- The market is not limited to brain implants. Recent funding also covers wearable EEG, peripheral nerve stimulation, spinal cord stimulation and focused-ultrasound neuromodulation, broadening the investable neurotechnology landscape.
- Most companies remain pre-commercial or in clinical translation, while Epitel stands out as a commercial-stage neurodiagnostics company already scaling an FDA-cleared wireless EEG platform.
- Precision Neuroscience alone represents roughly 60% of the lower-bound dollar value represented by these 12 financings, making the current neurotechnology funding picture unusually concentrated around one late-stage BCI round.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
We keep an up-to-date report on neurotech. Have a look ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Summary table of the latest funding deals in the neurotechnology market as of October 2026
We define the neurotechnology market as products that directly measure, stimulate, or computationally interface with the human nervous system for clinical or validated functional outcomes.
We include neurodevices and their enabling software such as BCIs, neuromodulation systems, and neurodiagnostic/monitoring tools, including EEG and related analytics.
We exclude pharmaceuticals, general-purpose imaging infrastructure not purpose-built for neuro, and standalone wellness or mental-health apps that do not directly capture or act on nervous-system signals.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Neurorevix | Sep 28, 2026 | >~$1.4M | Angel | BCI & Precision Neuromodulation |
| Precision Neuroscience | Sep 24, 2026 | $250M | Series D | Cortical BCI & Neural Interfaces |
| BCI-Sonics | Sep 22, 2026 | ~$29M | Pre-Series A | Non-invasive BCI & Ultrasound Neuromodulation |
| UCANACT | Sep 15, 2026 | ~$0.92M | Pre-seed | Assistive BCI & Neural Decoding |
| Shenyi Technology | Aug 31, 2026 | >~$1.4M | Angel | EEG & Non-invasive Neuromodulation |
| Sisheng Technology | Aug 18, 2026 | >~$1.4M | Seed+ | Ultrasound BCI & Neuro-AI |
| WE-LINKING Medical | Aug 17, 2026 | >~$14M | Undisclosed | Implantable BCI & Neuroprosthetics |
| Leadinno Medical Valley | Aug 17, 2026 | >~$28M | Series B+ & B++ | Implantable Neuromodulation & Brain-Spine Interfaces |
| Futong Huizhi | Aug 11, 2026 | >~$1.4M | Angel | EEG & Focused-Ultrasound Neuromodulation |
| Active Technology | Aug 3, 2026 | ~$46M | Angel | Invasive BCI & Neural Implants |
| Aurenar | Jul 28, 2026 | $5.7M | Seed | Peripheral Neuromodulation |
| Epitel | Jul 28, 2026 | $26M | Series B | Wearable EEG & Neurodiagnostics |
All the latest funding deals in the neurotechnology market as of October 2026
Neurorevix raised tens of millions of RMB in an angel financing in September 2026
When was it?
Neurorevix announced the financing on September 28, 2026.
Who are they?
Neurorevix develops flexible neural electrodes, BCI chips and adaptive algorithms for brain-computer interfaces and precision closed-loop nerve stimulation.
Geographical focus?
Neurorevix is based in Beijing and is initially focused on clinical development and commercialization in China.
Why do we include them in the neurotechnology market?
Neurorevix directly interfaces with neural signals and delivers targeted stimulation, placing the company in the BCI and precision neuromodulation categories.
What is the company stage?
Neurorevix is at an early clinical and product-development stage, moving its core neural-interface platform toward clinical products.
How much did they raise?
Neurorevix raised tens of millions of RMB, representing at least roughly $1.4M, although the exact amount was not disclosed.
What round is it?
Neurorevix described the financing as an angel round.
Why did they raise?
Neurorevix raised the capital to accelerate clinical translation and industrialization of its BCI and closed-loop neuromodulation technologies.
These pages are excerpts from our report. See the rest ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Precision Neuroscience raised $250M in a Series D in September 2026
When was it?
Precision Neuroscience announced the Series D on September 24, 2026.
Who are they?
Precision Neuroscience develops the Layer 7 Cortical Interface, a thin electrode array that records high-resolution cortical activity from the brain's surface.
Geographical focus?
Precision Neuroscience is U.S.-based and is developing its clinical network across major American medical institutions.
Why do we include them in the neurotechnology market?
Precision Neuroscience directly records cortical electrical activity, placing the company in the minimally invasive BCI and clinical neural-interface categories.
What is the company stage?
Precision Neuroscience is at a late clinical and pre-commercial stage, with more than 100 procedures completed across 18 medical institutions.
How much did they raise?
Precision Neuroscience raised $250M in this financing.
What round is it?
Precision Neuroscience raised a Series D round.
Why did they raise?
Precision Neuroscience raised the capital to expand clinical programs, advance regulatory work and build the infrastructure required for commercialization.
BCI-Sonics raised roughly $29M in a Pre-Series A in September 2026
When was it?
BCI-Sonics announced the financing on September 22, 2026.
Who are they?
BCI-Sonics develops AI-guided focused-ultrasound systems that stimulate targeted brain regions and integrate neural sensing for personalized treatment.
Geographical focus?
BCI-Sonics is based in Shanghai and is initially developing its clinical neurotechnology platform for the Chinese market.
Why do we include them in the neurotechnology market?
BCI-Sonics directly modulates neural activity and incorporates brain-signal feedback, placing it in non-invasive BCI and ultrasound neuromodulation.
What is the company stage?
BCI-Sonics is at an early clinical-validation stage, with developed products and ongoing clinical research.
How much did they raise?
BCI-Sonics raised RMB 200M, equivalent to roughly $28M to $30M.
What round is it?
BCI-Sonics raised a Pre-Series A round.
Why did they raise?
BCI-Sonics raised the capital for product development, technical hiring, clinical research and expansion of its AI infrastructure.
UCANACT raised about $0.92M in pre-seed funding in September 2026
When was it?
UCANACT announced the financing on September 15, 2026.
Who are they?
UCANACT develops software that converts recorded brain signals into computer actions and speech for people with severe motor disabilities.
Geographical focus?
UCANACT is based in the Netherlands and is initially developing its technology for European clinical and home-use settings.
Why do we include them in the neurotechnology market?
UCANACT computationally decodes neural signals into functional communication, placing the company in assistive BCI and neural-decoding software.
What is the company stage?
UCANACT is at the pre-seed stage and is moving academic BCI research toward a clinically usable product.
How much did they raise?
UCANACT raised €800,000, equivalent to approximately $0.92M.
What round is it?
UCANACT raised a pre-seed round.
Why did they raise?
UCANACT raised the capital for product development, clinical studies, market-access work, early commercialization and key hires.
Prefer verified numbers to headlines? Our report is here ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Shenyi Technology raised more than $1.4M in an angel round in August 2026
When was it?
Shenyi Technology announced the financing on August 31, 2026.
Who are they?
Shenyi Technology develops AI-enabled non-invasive BCI technology, including EEG wearables and closed-loop temporal-interference neuromodulation systems.
Geographical focus?
Shenyi Technology is based in Shenzhen and is initially targeting China's clinical and consumer neurotechnology markets.
Why do we include them in the neurotechnology market?
Shenyi Technology directly measures EEG activity and stimulates neural circuits, placing it in EEG, non-invasive BCI and neuromodulation.
What is the company stage?
Shenyi Technology is at an angel-stage product-development phase after being founded in 2025.
How much did they raise?
Shenyi Technology raised more than RMB 10M, equivalent to more than roughly $1.4M.
What round is it?
Shenyi Technology raised an angel round.
Why did they raise?
Shenyi Technology raised the capital to develop its closed-loop neuromodulation systems and EEG products for applications including sleep and depression.
Sisheng Technology raised tens of millions of RMB in a Seed+ round in August 2026
When was it?
Sisheng Technology announced the financing on August 18, 2026.
Who are they?
Sisheng Technology develops AI-driven focused-ultrasound brain-computer interfaces, multimodal brain-data systems and neuro-AI tools.
Geographical focus?
Sisheng Technology is based in China and is initially focused on medical neurotechnology and clinical applications in the domestic market.
Why do we include them in the neurotechnology market?
Sisheng Technology uses focused ultrasound to interact directly with neural activity, placing it in ultrasound BCI and neuromodulation.
What is the company stage?
Sisheng Technology is at a Seed+ stage and is advancing from technology development toward medical-device products and clinical validation.
How much did they raise?
Sisheng Technology raised tens of millions of RMB, representing at least roughly $1.4M, with the exact amount undisclosed.
What round is it?
Sisheng Technology raised a Seed+ round.
Why did they raise?
Sisheng Technology raised the capital for ultrasound BCI research, medical-device development, brain-data infrastructure and team expansion.
WE-LINKING Medical raised more than $14M for its implantable BCI platform in August 2026
When was it?
WE-LINKING Medical announced the financing on August 17, 2026.
Who are they?
WE-LINKING Medical develops medical-grade implantable BCI systems spanning cortical electrodes, intracranial EEG electronics, neural chips and integrated interfaces.
Geographical focus?
WE-LINKING Medical is based in China and is initially focused on clinical applications for neurological functional restoration.
Why do we include them in the neurotechnology market?
WE-LINKING Medical builds systems that directly record and interface with brain activity, placing it in implantable BCI and neuroprosthetic interfaces.
What is the company stage?
WE-LINKING Medical is in clinical translation and is working toward medical-device registration and broader manufacturing capability.
How much did they raise?
WE-LINKING Medical raised more than RMB 100M, equivalent to more than roughly $14M.
What round is it?
WE-LINKING Medical did not publicly disclose a conventional round designation for this financing.
Why did they raise?
WE-LINKING Medical raised the capital for clinical validation, regulatory registration, manufacturing expansion and new neural-restoration applications.
Want to know who is really ahead? Our report is here ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Leadinno Medical Valley raised more than $28M across B+ and B++ financings in August 2026
When was it?
Leadinno Medical Valley announced the financings on August 17, 2026.
Who are they?
Leadinno Medical Valley develops wireless implantable spinal-cord and peripheral-nerve stimulation systems alongside closed-loop and brain-spine interface technologies.
Geographical focus?
Leadinno Medical Valley is based in Beijing and initially targets neurological disorders and chronic-pain applications in China.
Why do we include them in the neurotechnology market?
Leadinno directly stimulates neural tissue and develops closed-loop neural interfaces, placing it in implantable neuromodulation and brain-spine interface technology.
What is the company stage?
Leadinno Medical Valley is in the clinical and regulatory stage, with its wireless spinal-cord stimulation platform moving toward commercialization.
How much did they raise?
Leadinno Medical Valley disclosed more than RMB 200M across the B+ and B++ financings, equivalent to more than roughly $28M.
What round is it?
Leadinno Medical Valley announced Series B+ and Series B++ financings together.
Why did they raise?
Leadinno Medical Valley raised the capital to commercialize wireless SCS, advance PNS trials and increase development of closed-loop and brain-spine interfaces.
Futong Huizhi raised tens of millions of RMB in an angel round in August 2026
When was it?
Futong Huizhi announced the financing on August 11, 2026.
Who are they?
Futong Huizhi develops EEG-guided focused-ultrasound systems that use neural signals to support closed-loop and precisely targeted brain stimulation.
Geographical focus?
Futong Huizhi is based in China and is initially focused on clinical neurotechnology applications in the domestic market.
Why do we include them in the neurotechnology market?
Futong Huizhi reads EEG activity and uses it to guide direct brain stimulation, placing the company in closed-loop neuromodulation and ultrasound BCI.
What is the company stage?
Futong Huizhi is at an angel-stage product and clinical-development phase.
How much did they raise?
Futong Huizhi raised tens of millions of RMB, representing at least roughly $1.4M, although the exact figure was not disclosed.
What round is it?
Futong Huizhi raised an angel round.
Why did they raise?
Futong Huizhi raised the capital for product development, registration-enabling clinical trials, hiring and expansion of its sales channels.
Active Technology raised roughly $46M in an angel round in August 2026
When was it?
Active Technology announced the financing on August 3, 2026.
Who are they?
Active Technology develops full-stack invasive BCI systems covering flexible neural electrodes, neural-interface chips, decoding algorithms and integrated implants.
Geographical focus?
Active Technology is based in Shanghai and is initially developing invasive clinical BCI products for the Chinese market.
Why do we include them in the neurotechnology market?
Active Technology directly records and interfaces with cortical neural activity, placing the company in invasive BCI and neural implants.
What is the company stage?
Active Technology is at an early clinical-translation stage despite raising substantial capital only months after the company's formation.
How much did they raise?
Active Technology raised RMB 330M, equivalent to approximately $46M.
What round is it?
Active Technology raised an angel round.
Why did they raise?
Active Technology raised the capital to expand facilities, add equipment, advance clinical trials and build its team for BCI commercialization.
We made a report out of all this. Take a look ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Aurenar raised $5.7M in seed funding for its neuromodulation platform in July 2026
When was it?
Aurenar announced the financing on July 28, 2026.
Who are they?
Aurenar develops a disposable ear-worn device that stimulates the vagus nerve to modulate inflammatory responses in critically ill patients.
Geographical focus?
Aurenar is U.S.-based and initially targets hospitals and intensive-care settings in the American market.
Why do we include them in the neurotechnology market?
Aurenar directly stimulates a peripheral nerve for a therapeutic outcome, placing the company in non-invasive peripheral neuromodulation.
What is the company stage?
Aurenar is in clinical development and is preparing its platform for pivotal studies and regulatory submission.
How much did they raise?
Aurenar raised $5.7M in this financing.
What round is it?
Aurenar raised a seed round.
Why did they raise?
Aurenar raised the capital to complete device development, perform verification and validation, and prepare for pivotal trials and regulatory submissions.
Epitel raised $26M in a Series B to scale wireless EEG monitoring in July 2026
When was it?
Epitel announced the financing on July 28, 2026.
Who are they?
Epitel develops REMI, an FDA-cleared wireless wearable EEG platform for long-duration brain monitoring and AI-assisted detection of seizure events.
Geographical focus?
Epitel is U.S.-based and serves hospitals, clinics and ambulatory monitoring programs in the American healthcare market.
Why do we include them in the neurotechnology market?
Epitel directly records electrical brain activity and analyzes neural signals, placing the company in wearable EEG and clinical neurodiagnostics.
What is the company stage?
Epitel is at the commercial growth stage, with an FDA-cleared product already being deployed by healthcare providers.
How much did they raise?
Epitel raised $26M in this financing.
What round is it?
Epitel raised a Series B round.
Why did they raise?
Epitel raised the capital to expand sales and customer teams, simplify provider deployment and increase access to long-duration ambulatory EEG monitoring.
If this is useful, the full report goes much further. Have a look ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us